anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Felbamate (3600 mg/day given QID) and low-dose valproate (15 mg/kg/day) were compared as monotherapy during a 112-day treatment period in a multicenter and a single-center double-blind efficacy trial. Both trials were conducted according to an identical study design. During a 56-day baseline period, all patients had at least four partial-onset seizures per 28 days and were receiving one antiepileptic drug at a therapeutic level, the most common being carbamazepine. In the multicenter trial, baseline seizure frequencies were 12.4 per 28 days in the Felbamate group and 21.3 per 28 days in the low-dose valproate group. In the single-center trial, baseline seizure frequencies were 18.1 per 28 days in the Felbamate group and 15.9 per 28 days in the low-dose valproate group. Patients were converted to monotherapy with Felbamate or low-dose valproic acid during the first 28 days of the 112-day treatment period. Study endpoints were completion of 112 study days or fulfilling an escape criterion. Criteria for escape relative to baseline were: (1) twofold increase in monthly seizure frequency, (2) twofold increase in highest 2-day seizure frequency, (3) single generalized tonic-clonic seizure (GTC) if none occurred during baseline, or (4) significant prolongation of GTCs. The primary efficacy variable was the number of patients in each treatment group who met escape criteria.

In the multicenter trial, the percentage of patients who met escape criteria was 40% (18/45) in the Felbamate group and 78% (39/50) in the low-dose valproate group. In the single-center trial, the percentage of patients who met escape criteria was 14% (3/21) in the Felbamate group and 90% (19/21) in the low-dose valproate group. In both trials, the difference in the percentage of patients meeting escape criteria was statistically significant (P<.001) in favor of Felbamate. These two studies by design were intended to demonstrate the effectiveness of Felbamate monotherapy. The studies were not designed or intended to demonstrate comparative efficacy of the two drugs. For example, valproate was not used at the maximally effective dose.
1. This idea is focused to the broad mass market in the medical health care domains and consumer durables sector. This is a unique, one of its kind and affordable solution to the medical health care domains and consumer durables sector. This is a durable product. 2. These technologies such as Intelligent (Smart) IV stands, intelligent (Smart) Oxygen stands provides doctors, nurses and patient's relatives its web access to monitor the Intravenous bags, Oxygen cylinders at the hospital or home or from anywhere in the world by using computers or cell phone applications. Software application provides virtual interfaces of real time status of the IV fluids and Oxygen administrated to the patients and provides the real time varying levels of the IV fluids in the IV bags and also Oxygen cylinder on the stand. Also this software provides various historical reports, trend reports on the IV and Oxygen administrated to the patients which will result in accurate inventory management. 3. Intelligent (Smart) patient's cot will provide doctors, nurses and patient's relatives its web access to the cot to track patient's movement, restlessness, availability and non availability from anywhere in the world by using computers or cell phone applications. Software application provides virtual interface of real time status of the movement patterns, restlessness of the patients. Also this software provides various historical reports, trend reports on the patient movement, restlessness, availability and non availability in their beds. 4. Intelligent (Smart) cooking gas stands at home, star hotels of different ranking, home Kitchens, fast food retailers, centralized kitchens, Kitchens of catering service providers, canteens of institutions etc. provides web access to the users to track and monitor the usage, quantity of the daily consumption and also the quantity remaining in the cylinders. Also this web application / software provides various historical reports, trend reports on the cooking gas used and the trend patterns which will result in accurate inventory management and avoid improper and excessive usages and wastages.
The invention belongs to the field of bone marrow cell morphology detection, and particularly relates to an automatic bone marrow cell morphology detection and verification system and a method. The invention adopts the technical scheme that the automatic detection and verification system for the bone marrow cell morphology comprises an image quality verification section, a counting interval verification section, a cell identification accuracy verification section and a disease association verification section. The image quality auditing plate is used for auditing whether the image generated by scanning the smear meets the requirements. And the counting interval auditing section is used for auditing whether the screening of the counting interval has problems. And the cell identification accuracy auditing block is used for detecting whether the cell identification is correct. Disease association review blocks are used to describe abnormal cells. The auditing system and the auditing method have the auditing feedback function, can compensate the cell identification data in statistics and reduce the workload of doctors.
Industrial process for the preparation of a naphthyridine carboxylic acid and its salts, of the general formula: ** formula ** in which r = h or r = a na ion, k, ca, etc., characterized by: Consider the 2-methyl-6-aminopyridine as the starting material which by reaction with the diethyl ethoxymethylenemalonate or with a mixture of ethyl orthoformate and diethyl malonate, diethyl 2-methyl-pyridine-6-aminomethylenemalonate is obtained. The reaction is carried out at a temperature between 100ºC and 150º c, until the evolution of ethyl alcohol ends. The diester thus obtained is cyclized at a temperature of 270ºC and 300º c, using as diphyl solvent. The product obtained is the ethyl ester of 7-methyl-1,8-naphthyridin-4-one-3-carboxylic acid. By hydrolysis of this compound in an alkaline medium and ethylation of the amine in position 1 with diethyl sulfate of 7-methyl-1,8-naphthyridin-4-one-3-carboxylic acid ethyl ester, we obtain 1-ethyl- 7-methyl-1,8-naphthyridin-4-one-3-carboxylic acid, independent of the order of the reactions, that is, saponify-ethylate or vice versa. The saponification reaction is carried out in aqueous alkaline medium and at a temperature between 70ºC and 90º c. And ethylation by intermittent addition of diethyl sulfate, also in aqueous medium. To obtain the inorganic salts, these are prepared by salification of 1-ethyl-7-methyl-1,8-naphthyridin-4-one-3-carboxylic acid with the corresponding hydroxide in aqueous medium and at a temperature between 20ºC and 50º c. . (Machine-translation by Google Translate, not legally binding)
INTRODUCTION: Olfactory disorders significantly affect individuals, diminishing their capacity to detect dangers, appreciate flavors, and engage socially. Despite their considerable impact on quality of life, these disorders often receive less attention compared to other sensory impairments. This review emphasizes the importance of olfactory function and explores both traditional and innovative diagnostic and therapeutic approaches.
AREAS COVERED: This review comprehensively covers the pathophysiology, diagnostic challenges, and treatment options for olfactory disorders. It delves into the nuances of different disorders, such as anosmia and parosmia, and discusses the array of diagnostic tools from traditional sniff tests to advanced imaging techniques. The review also evaluates therapeutic strategies, from pharmacological treatments to emerging therapies like electrical stimulation and regenerative medicine, highlighting recent advances in the field.
EXPERT OPINION: Current insights suggest a growing recognition of the significance of olfactory disorders, driven by recent pandemics and advances in diagnostic and therapeutic technologies. Future perspectives indicate a promising direction toward more personalized medicine approaches and enhanced regenerative therapies. Continuous research and improved clinical awareness are critical for evolving the management strategies of olfactory impairments, potentially leading to better patient outcomes and quality of life enhancements.
Lipopolysaccharide (LPS) in blood circulation causes endotoxemia and is linked to various disease conditions. Current treatments focus on preventing LPS from interacting with its receptor Toll-like receptor 4 (TLR4) and reducing inflammation. However, our body has a natural defense mechanism: reticuloendothelial cells in the liver rapidly degrade and inactivate much of the circulating LPS within minutes. But this LPS clearance mechanism is not perfect. Excessive LPS that escape this clearance mechanism cause systemic inflammatory damage through TLR4. Despite its importance, the role of reticuloendothelial cells in LPS elimination is not well-studied, especially regarding the specific cells, receptors, and mechanisms involved. This gap hampers the development of effective therapies for endotoxemia and related diseases. This review consolidates the current understanding of LPS clearance, narrates known and explores potential mechanisms, and discusses the relationship between LPS clearance and LPS signaling. It also aims to highlight key insights that can guide the development of strategies to reduce circulating LPS by way of bolstering host defense mechanisms. Ultimately, we seek to provide a foundation for future research that could lead to innovative approaches for enhancing the body's natural ability to clear LPS and thereby lower the risk of endotoxin-related inflammatory diseases, including sepsis.
Recently, various studies have been devoted to the study of transient receptor potential vanilloid member 1 (TRPV1)-related diseases, potential drugs, and related mechanisms. The objective of this investigation was to examine the significant areas and cutting-edge developments in TRPV1 study within recent decades. Articles or reviews were obtained from the Web of Science Core Collection. VOSviewer 1.6.18 and CiteSpace 6.1 R2 software were utilized to examine publication growth, distribution by country/region, institution, journal, authorship, references, and keywords. The software identified keywords with a high citation burstiness to determine emerging topics. From 1990 to 2023, the annual global publications increased by 62,000%, from 1 to 621. Journal of neuroscience published the most manuscripts and Nature produced the highest citations. The USA, Seoul National University and Di marzo V were the most productive and impactful institution, country, and author, respectively. "TRPV1," "Capsaicin receptor," "Activation," and "Pain" are the most important keywords. The burst keywords "TRPV1 channel," "Oxidative stress," "TRPV1 structure," and "Cancer" are supposed to be the research frontiers. The present study offers valuable insights into the understanding of TRPV1 and pain-related conditions. The research on TRPV1 has demonstrated a steady increase in studies related to pain-related diseases in the past few decades. The significance of TRPV1 in cancer pathogenesis and the resolution of its structure will emerge as a new academic trend in this field, providing direction for more widespread and comprehensive studies in the future.
Patients will receive P16_37-63 peptide (100 μg) combined with Montanide® ISA-51 VG subcutaneously once a week for four weeks, followed by a 4 week rest period (1 cycle). The vaccination is to be started one week before the initiation or continuation of the cisplatin-based chemotherapy.
Initial 2.5 mg/day for two weeks, then 5 mg/day for two weeks, and then 10 mg/day for two weeks. Systolic blood pressure will be measured before and following each titration The participant will receive the final titration dose for a total of six weeks.. The drug is administered as an oral tablet once daily.
EQU-201 is a Phase 2 randomized, double-blind, placebo-controlled study to evaluate dose-ranging safety, tolerability, and exploratory efficacy of adjunctive EQU-001 using the continuous reassessment method (CRM). 10 participants diagnosed with epilepsy according to the International League Against Epilepsy (ILAE) Classification of the Epilepsies 2017 criteria whose seizures are uncontrolled on one to four concomitant antiepileptic drugs (AEDs) for ≥4 weeks will be enrolled in 4 dose cohorts (10 mg, 20 mg, 40 mg, 60 mg) The participants will be randomized 4:1, drug to placebo. The dosing is for 12 weeks, after which, safety data will be reviewed post 14 days to determine whether the next cohort can be opened. Once the 12-week study dosing period is complete, all subjects may enroll in an open-label extension, during which period investigators may make dose adjustments down to 20 mg and up 80 mg.

This study of EQU-001 will provide safety of a range of doses, tolerability, and PK data in patients with epilepsy and aims to identify drug-specific DLTs and MTD. The PK component will characterize the PK of EQU-001 to inform dosing and may help to correlate exposures with any DLTs or other treatment-related AEs. The open label extension component will provide data on subject safety, tolerability and efficacy.
INTRODUCTION: About 17-80% stroke survivors experience the deficit of upper limb function, which strongly influences their independence and quality of life. Robot-assisted training and functional electrical stimulation are commonly used interventions in the rehabilitation of hemiplegia upper extremities, while the effect of their combination remains unclear. The aim of this trial is to explore the effect of robot-assisted upper limb training combined with functional electrical stimulation, in terms of neuromuscular rehabilitation, compared with robot-assisted upper limb training alone.
METHODS: Individuals (n = 60) with the first onset of stroke (more than 1 week and less than 1 year after stroke onset) will be considered in the recruitment of this single-blinded, three-arm randomized controlled trial. Participants will be allocated into three groups (robot-assisted training combined with functional electrical stimulation group, robot-assisted training group, and conventional rehabilitation therapies group) with a ratio of 1:1:1. All interventions will be executed for 45 min per session, one session per day, 5 sessions per week for 6 weeks. The neuromuscular function of the upper limb (Fugl-Meyer Assessment of upper extremity), ability of daily life (modified Barthel Index), pain (visual analogue scale), and quality of life (EQ-5D-5L) will be assessed at the baseline, at the end of this trial and after 3 months follow-up. Two-way repeated measures analysis of variance will be used to compare the outcomes if the data are normally distributed. Simple effects tests will be used for the further exploration of interaction effects by time and group. Scheirer-Ray-Hare test will be used if the data are not satisfied with normal distribution.
DISCUSSION: We expect this three-arm randomized controlled trial to explore the effectiveness of robot-assisted training combined with functional electrical stimulation in improving post-stroke upper limb function compared with robot-assisted training alone.
TRIAL REGISTRATION: Effect of upper limb robot on improving upper limb function after stroke, identifier: ChiCTR2300073279. Registered on 5 July 2023.
The invention relates to recombinant baculovirus virus-like particles of a porcine circovirus (PCV) 2 type codon optimized OFRF2 gene and belongs to the field of biological pharmacy. All PCV2 ORF2 sequences undergo comparative analysis to obtain a synthetic codon optimized PCV2 ORF2 sequence which is named as YHsfORF2. YHsfORF2 undergoes cloning and transfection to obtain recombinant baculovirus vFBHYHsfORF2. The codon optimized ORF2 gene can be highly-efficiently expressed in recombinant virus and can form virus-like particles. The invention also relates to an application of the recombinant virus in the field of vaccine. An animal immune protection test indicates that the recombinant virus inactivated vaccine can stimulate a body to produce an efficient immune response, effectively inhibits the replication of PCV2 in animal body and has a good immunoprophylaxis protection effect against PCV2 infection.
This multicenter study will be conducted in 2 parts (Part 1 and 2). Part 1 of the study is a multicenter, randomized, single-blind, placebo-controlled portion, ascending multiple oral dose study designed to evaluate the safety, tolerability, and PK of ascending multiple oral doses of SEP-363856 and its metabolite SEP-363854 in male and female subjects with schizophrenia. Part 1 This study will determine the MTD for once-daily multiple oral administration of SEP-363856, and characterize the plasma and urine PK profiles of SEP-363856 and its metabolite SEP-363854 in male and female subjects with schizophrenia. The effect of SEP-363856 on the PANSS, CGI-S, and CDSS scales will also be assessed. For each of the dose-escalation cohorts, 12 subjects (9 active subjects and 3 placebo subjects) will be dosed for 7 consecutive days with serial collection of PK blood samples after the first and last doses, and daily collection of trough PK blood samples. An attempt will be made to have at least one-third of subjects in each cohort be female. Part 2 of the study is an open-label safety and tolerability study designed to gain longer-term safety and tolerability data for 75 mg SEP-363856 given once-daily for 28 days in male and female subjects with schizophrenia. The effect of SEP-363856 on the PANSS, CGI-S, and CDSS scales will also be assessed. In Part 2, 16 subjects will be dosed.
Despite its widespread use in clinical practice, the effectiveness of natalizumab extended interval dosing (EID) adopted from treatment start across different treatment intervals and individual modifiers (body mass index - BMI) is still under-investigated. Here, seven-hundred and forty-five multiple sclerosis (MS) patients, exposed to natalizumab for 3.30 ​± ​1.34 years, were retrospectively enrolled in an observational multicenter study. After stratifying patients in EID or standard interval dosing (SID), we assessed differences in time to relapse, MRI activity and Expanded Disability Status Scale (EDSS) progression. The primary analysis was conducted on patients exposed to EID interval from 5 weeks and 1 day to 7 weeks, while a secondary analysis included also EID periods up to 8 weeks. An additional analysis explored the impact of BMI. No differences in time to first relapse, time to radiological activity, time to EDSS progression or time to EDA (evidence of disease activity) were detected between SID and EID group (EID interval from 5 weeks to 1 day to 7 weeks). When including EID periods from 7 weeks and 1 day to 8 weeks, the EID group showed a trend towards higher risk of experience clinical relapses than the SID group. A higher EDA risk was also identified in EID patients with BMI above median. In conclusion, a higher risk of relapses seems to occur for EID above 7 weeks. Independently from the EID scheme adopted, higher BMI increases the risk of EDA in these patients.
Food allergy affects 6-8 percent of children in the United States. In young children, reactions to egg can range from hives to severe life threatening allergic reactions called anaphylaxis. Current treatment for food allergy is complete avoidance of the food and to carry antihistamines and self-injectable epinephrine if an accidental reaction occurs. However, accidental exposure to allergens in processed foods may be difficult to avoid. Currently, several therapeutic strategies are being investigated to prevent and treat food allergies. Since immunotherapy injections for food allergy are associated with a high rate of allergic reactions, alternate approaches to treatment are needed. Oral (by mouth) immunotherapy (OIT) is one approach that has been tried in some studies in the treatment of food allergies. The purpose of this study is to compare baked foods with egg versus (vs.) egg OIT. The intent of the study is to investigate if participants will be able to consume egg after taking baked foods with egg or egg OIT for a period of time and then stopping for a certain period. This is referred to as tolerance or sustained unresponsiveness. This study will evaluate the effectiveness of the egg OIT vs. baked egg by having each participant ingest egg white solid or baked foods with egg. This will be done over 2 years.

This study will last 2 years. All eligible subjects will receive a baked egg oral food challenge (OFC). Those who pass the baked egg OFC will then have a 2 gm egg OFC. Those who react to the egg OFC will be randomized to Baked Egg or Egg OIT. Individuals who do not pass the initial baked egg OFC will be assigned to Egg OIT. Those who pass the egg OFC will not be eligible for the study and will be followed per site standard of care. All eligible and enrolled subjects will have a 1-year and a 2-year OFC.

At selected visits, blood and urine collection, physical examination, prick skin tests, and atopic dermatitis and asthma evaluations will occur.
Inflammatory bowel disease (IBD) and atherosclerosis (AS) are both common chronic inflammatory diseases with similar pathophysiological mechanisms. Some studies have shown that IBD patients are at increased risk for early atherosclerosis, myocardial infarction and venous thrombosis. Here we set up a hybrid mouse model associated with atherosclerosis and acute colitis in order to investigate the interplay of the two diseases. We fed ApoE-/- mice with high fat diet to establish atherosclerosis model, and used animal ultrasound machine to detect the artery of mice noninvasively. Then a new hybrid model of atherosclerosis and acute colitis was prepared by drinking water for 7 days. At the end of the experiment, the hybrid model mice showed typically pathological and intuitionistic changes of atherosclerosis and acute colitis. We found the shortened colon length, high histopathological scores of the colon with mucosal erosion and necrosis, hyperlipidemia, a plaque-covered mouse aorta and plaque with foam cells and lipid deposition in the hybrid model group, which proved that the hybrid model was successfully established. At the same time, ultrasonic detection showed that the end-diastolic blood flow velocity and the relative dilation value were decreased, while systolic time / diastolic time, the wall thickness, systolic diameters as well as diastolic diameters were gradually increased, and statistical significance appeared as early as 8 weeks. We clearly described the process of establishing a hybrid model of atherosclerosis and acute colitis, which might provide a repeatable platform for the interaction mechanism exploring and drug screening of atherosclerosis and inflammatory bowel disease in preclinical study.
Patients will be recruited to wear a outpatient mobile cardiac monitoring device for detection of atrial fibrillation in patients with a history of stroke of known case. Their are not study treatments or interventions, this is an observational trial. Eligible patients must be \>50 years old, have a history of ischemic stroke or transient ischemic attack with a documented brain infarction within the prior 12 months. If patients are on anticoagulation therapies, they are eligible for enrollment if the long-term strategy for stroke prevention is anti-platelet therapy and not the oral anti-coagulant itself. Patients must not have an detection of AF and then must successfully activate the lifeStar device for enrollment. At the end of three weeks, the LifeStar device will be over-read and scored for the presence of AF and other clinically significant arrhythmias by the study electrophysiologist, who will determine the occurrence and burden of AF.